NVS  Novartis Ag




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-0.97 (-1.17%)

Growth Price

Overvalued by 31.59%

Stability Price

Overvalued by 82.21%

Company Metrics

  • P/E 29.25
  • P/S 3.97
  • P/B 2.72
  • EPS 2.80
  • Cash ROIC 11.30%
  • Cash Ratio 0.16
  • Dividend 2.72 / 3.25 %
  • Avg. Vol. 1.81M
  • Shares 2.38B
  • Market Cap. 195.07B

Company Description

Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division offers prescription medicines in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; integrated hospital care; and other additional products. The company's Vaccines... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Revenue Update on Novartis AG (ADR)(NYSE:NVS)
Trade Calls - Jul 26, 2016
Novartis AG (ADR)(NYSE:NVS) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 19, 2016.
Are Analysts Bullish Novartis AG (ADR) (NYSE:NVS) After Last Week? - Consumer Eagle
Novartis AG (NYSE:NVS) Short Interest Decreased By 10.78% - Press Telegraph
Novartis AG (ADR) (NYSE:NVS) Biosimilars Roadmap
Market Exclusive - Jun 20, 2016
Novartis AG (ADR) (NYSE:NVS) is in the process of tripling its portfolio of biosimilar drugs by 2020. The company is particularly working to develop alternatives to blockbuster drugs such as Johnson & Johnson (NYSE:JNJ) Remicade and Amgen, Inc.
Novartis AG (ADR) Has Enough Arsenal to Steer Clear of Ongoing Rout - Bidness ETC
How Novartis AG (NYSE:NVS) trades after earning announcements? - Zergwatch
Can Novartis AG (ADR) Reach Financial Stability via Restructuring?
Business Finance News - May 20, 2016
As Novartis AG (ADR) (NYSE:NVS) head of pharmaceuticals, David Epstein, announced his departure from the company, it initiated the process of restructuring the business portfolios.
Novartis AG (ADR) (NYSE:NVS) To Pay $25 Million Over Bribery Allegations
Market Exclusive - Mar 25, 2016
Last year GlaxoSmithKline plc (ADR) (NYSE:GSK) posted a 17% drop in sales as a state-led campaign on drug prices affected returns.
How Many Heart Failure Deaths Can Novartis AG (ADR) (NYSE:NVS) Entresto Reduce?
Market Exclusive - Jun 23, 2016
A fresh analysis of Novartis AG (ADR) (NYSE:NVS) drug Entresto has shown that it can significantly reduce heart failure deaths.
Novartis AG (ADR) 2Q Earnings: Here's What To Expect?
Bidness ETC - Jul 18, 2016
Novartis AG (NYSE:NVS) is scheduled to report its second-quarter of fiscal 2016 (2QFY16) earnings results on July 19, 2016, before markets open.
Novartis AG (ADR) (NYSE:NVS): Reviewing Earnings Estimates - Post Registrar
No One Is Above The Law; Novartis AG (ADR) Has To Pay
Business Finance News - Nov 23, 2015
Novartis AG (ADR) (NYSE:NVS) has concluded a settlement with the U.S. Justice Department regarding the drugmaker's paid rebate to the specialty pharmacies and reached an agreement to make certain changes on interactions with them.
Novartis AG (ADR) Aiming to Target Biosimilar Market by 2020
Business Finance News - Jun 20, 2016
By 2020, Novartis AG (NYSE:NVS) plans to launch a number of biosimilar versions of the blockbuster drugs in order to enter multiple therapeutic markets.
Pfizer Inc, Sanofi SA (ADR), Novartis AG (ADR): Who Will Acquire Medivation Inc?
Business Finance News - May 4, 2016
As the merger and acquisition (M&A) spree is booming, multiple pharmaceutical companies have put Medivation Inc. (NASDAQ:MDVN) on the top of their acquisition list.
Novartis AG (ADR) First-Quarter Earnings: What to Expect?
Bidness ETC - Apr 20, 2016
Novartis AG (ADR) (NYSE:NVS) is set to announce its financial results for the first quarter of 2016 (1Q) on Thursday, April 21.